Hirtle Callaghan & Co’s Fortress Biotech FBIO Stock Holding History

Hirtle Callaghan & Co’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-138	Closed	-$5K	–	142
2014 Q4	$5K	Hold	138	–	–	﹤0.01%	462
2014 Q3	$4K	Hold	138	–	–	﹤0.01%	512
2014 Q2	$4K	Hold	138	–	–	﹤0.01%	546
2014 Q1	$4K	Hold	138	–	–	﹤0.01%	534
2013 Q4	$5K	Hold	138	–	–	﹤0.01%	503
2013 Q3	$14K	Hold	138	–	–	﹤0.01%	455
2013 Q2	$18K	Buy	+138	New	+$20.3K	0.21%	44

Other funds holding FBIO

Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BGA

Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SIM

Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

Hirtle Callaghan & Co's FBIO Position: Q1 2015 in Review

Hirtle Callaghan & Co sold out of Fortress Biotech (FBIO) in Q1 2015, closing a stake of 138 shares — an estimated $5K sold.

Hirtle Callaghan & Co first reported a position in FBIO in Q2 2013 and held it in 7 quarters. The position peaked at $18K in Q2 2013. 49 funds tracked by Wall St. Rank hold FBIO as of Q1 2015.

Hirtle Callaghan & Co reported no remaining Fortress Biotech position as of Q1 2015 after selling out during the quarter.
Hirtle Callaghan & Co sold 138 Fortress Biotech shares in Q1 2015, an estimated $5K.
Hirtle Callaghan & Co first reported a position in Fortress Biotech in Q2 2013 and held it in 7 quarters.
Hirtle Callaghan & Co's Fortress Biotech position peaked at $18K in Q2 2013.
49 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2015.

Based on Hirtle Callaghan & Co's 13F filing for Q1 2015, filed 15 May 2015.